Your browser doesn't support javascript.
loading
A Response to the Letter to the Editor: Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
Higashiyama, Ryoko I; Yoshida, Tatsuya.
Affiliation
  • Higashiyama RI; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Yoshida T; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. Electronic address: tayoshi@ncc.go.jp.
J Thorac Oncol ; 19(9): e33-e34, 2024 Sep.
Article in En | MEDLINE | ID: mdl-39242142
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Antibodies, Monoclonal, Humanized / Lung Neoplasms Limits: Humans Language: En Journal: J Thorac Oncol Year: 2024 Document type: Article Affiliation country: Japón Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Antibodies, Monoclonal, Humanized / Lung Neoplasms Limits: Humans Language: En Journal: J Thorac Oncol Year: 2024 Document type: Article Affiliation country: Japón Country of publication: Estados Unidos